Patrick Vermersch

Active 1991–2025

131
Papers
18,142
Citations
71
h-index
124
i10-index

Citations

Citations per year for Patrick Vermersch1949: 1 citations1975: 1 citations1987: 1 citations1990: 2 citations1992: 3 citations1994: 2 citations1995: 9 citations1996: 9 citations1997: 29 citations1998: 39 citations1999: 38 citations2000: 38 citations2001: 40 citations2002: 63 citations2003: 40 citations2004: 57 citations2005: 41 citations2006: 88 citations2007: 111 citations2008: 102 citations2009: 107 citations2010: 122 citations2011: 135 citations2012: 138 citations2013: 100 citations2014: 106 citations2015: 114 citations2016: 116 citations2017: 120 citations2018: 163 citations2019: 527 citations2020: 642 citations2021: 549 citations2022: 515 citations2023: 342 citations2024: 653 citations2025: 379 citations2026: 10 citations1950–1974: no citations, so these years are not shown1976–1986: no citations, so these years are not shown1988–1989: no citations, so these years are not shown1991: no citations, so this year is not shown1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,464 citing papers, 17.6% of this breakdownUnited Kingdom: 754 citing papers, 9.1% of this breakdownGermany: 657 citing papers, 7.9% of this breakdownFrance: 603 citing papers, 7.2% of this breakdownItaly: 587 citing papers, 7% of this breakdownNetherlands: 383 citing papers, 4.6% of this breakdownCanada: 377 citing papers, 4.5% of this breakdownSpain: 324 citing papers, 3.9% of this breakdownSwitzerland: 284 citing papers, 3.4% of this breakdownChina: 262 citing papers, 3.1% of this breakdownAustralia: 241 citing papers, 2.9% of this breakdownSweden: 211 citing papers, 2.5% of this breakdown
0%17.6%Other 26.3%

Fields

  • Medicine80.8%
  • Neuroscience8.1%
  • Biochemistry, Genetics and Molecular Biology6.5%
  • Immunology and Microbiology1.8%
  • Computer Science0.7%
  • Engineering0.5%
  • Other1.6%

Topics

  • Multiple Sclerosis Research Studies14.9%
  • Peripheral Neuropathies and Disorders5.8%
  • Dementia and Cognitive Impairment Research5.8%
  • Alzheimer's disease research and treatments5.1%
  • Polyomavirus and related diseases2.4%
  • Systemic Lupus Erythematosus Research2.1%
  • Other63.9%

Coauthors

All papers

Open in search
  1. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mihaela Bejinariu, Florian Then Bergh, Arnfin Bergmann, Evanthia Bernitsas, Achim Berthele, Virender Bhan, Felix Bischof, Randall J. Bjork, Gregg Blevins, Matthias Boehringer, Thomas Boerner, Robert Bonek, James D. Bowen, Allen C. Bowling, Alexey Boyко, Cavit Boz, Vera Bracknies, Stefan Braune, Vincenzo Brescia Morra, Bruno Brochet, Waldemar Brola, Paul Brownstone, M Brozman, Donald Brunet, Ioan Buraga, Margaret Burnett, Mathias Buttmann, Helmut Butzkueven, Jonathan Cahill, Jonathan Calkwood, William Camu, Mark Cascione, G. Castelnovo, Diego Centonze, João Cerqueira, Andrew Chan, Andrea Cimprichová, Stanley Cohan, Giancarlo Comi, Jill Ker Conway, Joanna A. Cooper, John R. Corboy, Jorge Correale, Brian Costell, David A. Cottrell, Patricia K. Coyle, Matthew Craner, Liying Cui, Luı́s Cunha, Anna Członkowska, Ana Silva, Joao de, de Sèze, Marc Debouverie, Jan Debruyne, D. Decoo, G. Defer, Tobias Derfuß, Norma Deri, Bhupesh Dihenia, Péter Diószeghy, Vladimír Donáth, Bénédicte Dubois, Martin Duddy, Pierre Duquette, Gilles Edan, Hüsnü Efendi, Stanton B. Elias, Peter Emrich, Bonaventura Casanova Estruch and 228 more - The Lancet 2018 cited by 925

  2. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

    Authors: , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 1992 cited by 1,776

  3. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

    Authors: , , , , , , , , , , - New England Journal of Medicine 2010 cited by 1,007

  4. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , И. В. Литвиненко, Ф. А. Хабиров, С А Сиверцева, Viera Hančinová, Ema Kantorová, María Luisa Martínez Ginés, Xavier Montalbán, Sara Eichau Maduano, José Meca-Lallana, Lluís Ramió‐Torrentà, Tetyanna Nehrych, V.M. Pashkovskyy, Sergii Moskovko, O. I. Kalbus, Marta Khavunka, Volodymyr Pryshchepa, Alla Goloborodko, Daniel Wynn, William Honeycutt, Sibyl Wray, Brian Steingo, Christopher LaGanke, DeRen Huang, John M. Hemphill, Lawrence Goldstick, Derrick Robertson - The Lancet Neurology 2021 cited by 192

  5. Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

    Authors: , , , , , , , , , , , , - Alzheimer s Research & Therapy 2023 cited by 94

  6. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , François Jacques, Yves Lapierre, Liesly Lee, Sarah A. Morrow, Michael Yeung, Michal Dufek, Eva Havrdová, Petr Kaňovský, Ivana Štětkářová, Marika Talábová, Jette Lautrup Frederiksen, Matthias Kant, Thor Petersen, Mads Ravnborg, Finn Sellebjerg, Laura Airas, Irina Elovaara, Juha-Pekka Erälinna, Taneli Sarasoja, Abdullatif Al Khedr, David Brassat, Bruno Brochet, William Camu, Marc Debouverie, David Laplaud, Christine Lebrun‐Frénay, Jean Pelletier, Patrick Vermersch, Sandra Vukusi, Karl Baum, Achim Berthele, Juergen Faiss, Peter Flachenecker, Reinhard Hohlfeld, Markus Krumbholz, Christoph Lassek, Mathias Maeurer, Sven G. Meuth, Tjalf Ziemssen, Orla Hardiman, Christopher McGuigan, Anat Achiron, Dimitrios Karussis, Roberto Bergamaschi, Vincenzo Brescia Morra, Giancarlo Comi, Salvatore Cottone, Luigi M.E. Grimaldi, Giovanni Luigi Mancardi, Luca Massacesi, Ugo Nocentini, Marco Salvetti, Elio Scarpini, Patrizia Sola, Gioacchino Tedeschi, María Trojano, Mauro Zaffaroni, Stephan Frequin, Raymond Hupperts, Joep Killestein, Hans M. Schrijver, Ronald Van Dijl, Erik van Munster, Maciej Czarnecki, Wiesław Drozdowski, Waldemar Fryze, Hanka Hertmanowska, Jan Ilkowski, Anna Kamińska, Gabriela Kłodowska-Duda and 90 more - The Lancet Neurology 2018 cited by 337

  7. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

    Authors: , , , , , , , , - Multiple Sclerosis Journal 2017 cited by 333

  8. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Orhan Aktaş, Patrick Vermersch, Celia Oreja‐Guevara, Gıancarlo Comı, Letizia Leocani, Elena García‐Martín, Friedemann Paul, Eva Havrdová, Elliot M. Frohman, Laura J. Balcer, Ari Green, Peter A. Calabresi, Pablo Villoslada - The Lancet Neurology 2016 cited by 333

  9. Inhibition of CD40L with Frexalimab in Multiple Sclerosis

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 85

  10. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria

    Authors: , , , , , , , , , , , , , , , , , - Multiple Sclerosis Journal 2014 cited by 305

  11. Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study

    Authors: , , , , , , , , , , , , , , - Annals of Clinical and Translational Neurology 2021 cited by 95

  12. Natural History of Multiple Sclerosis with Childhood Onset

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2007 cited by 591

  13. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pierre Branger, Mouloud Abrous, Hélène Zéphir, Julie Petit, Sandra Vukusic, Céline Gelet, Clarisse Carra‐Dallière, Xavier Ayrignac, Mélanie Russello, David Laplaud, Alina Gaultier, Fabienne Le Frère, Céline Callier, Cynthia Caillon, Eglantine Gueydan, Céline Louapre, Damien Galanaud, Aurelian Ungureanu, Sylvie Coudoin, Benjamin Hébant, Emmanuel Gerard, Christine Vimont, Damien Biotti, Fabrice Bonneville, Noellie Freitas, Taşkın Duman, Erhan Kilic, Melih Tütüncü, Uğur Uygunoğlu, Sena Destan, Sedat Şen, Christoph Friedli, Franca Wagner, Lea Weber, Annaig Tchoubar, Émilie Dumont, Asli Eryilmaz, Tanguy Roman, Christopher Pelletreau, Aurélie Grateau, Yanica Mathieu, Sarhan Yaïche, Felix Rintelen, Isabel Firmino, Aymeric De Chastenier, Amel Gheribenblidia, Burcu Zeydan - JAMA Neurology 2023 cited by 89

  14. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marcos Burgos, Juan Carlos Giugni, Juan Jose Martin Artesi, Juan Ignacio Rojas, Daniel Raul Zuin, Hugo Osvaldo Videla, Jorge Daniel Correale, Geraldine G. Luetic, Suzanne Hodgkinson, Jeannette Lechner-Scott, John Parratt, Noel Saines, Stephen Reddel, Tissa Wijeratne, Bruce Taylor, Florian Deisenhammer, Gerhard Traxler, Fritz Leutmezer, Peter Wipfler, Joerg R. Weber, Christian Lampl, Emmanuel Bartholome, Dominique Dive, Nele Glibert, Gaetano Perrotta, Vincent Pesch, Maarten Buyle, Bart Wijmeersch, Barbara Willekens, Edin Basagic, Enra Mehmedika Suljic, Inge Klupka-Sarić, Maya Danovska, Maria Dimitrova, Krasimir Genov, Alim Izmaylov, Radoslav Mavrov, Ivan Milanov, Valcho Naydenov, Penko Shotekov, Ivaylo Tarnev, Latchezar Traykov, Francois Emond, Daniel Selchen, Donald Rivest, Lisa Sabella, Ludivine Witkowski, Alexander Saveriano, Addinson Rene Bolano Solano, Cesar Augusto Franco Ruiz, Andrea Catalina Nassar Tobon, Carlos Alberto Navas Cardozo, Antonio Schlesenger, Javier Dario Triana, Osvaldo Elias Lara Sarabia, Luis Alfonso Zarco Montero, Jorge Andres Jimenez Arango, Silvio Basic, Marija Bosnjak Pasic, Silva Butkovic Soldo, Mario Habek, Spomenka Kidjemet-Piskac, Meri Matijaca, Vladimira Vuletic, Radek Ampapa, Michal Dufek, Marketa Grunermelova, Jan Mares, Alena Martinkova, Marek Peterka and 607 more - The Lancet Neurology 2024 cited by 72

  15. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging

    Authors: , , , , , , , - Journal of the Neurological Sciences 1993 cited by 928

  16. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ν. Fakas, Nikolaos Grigoriadis, D. Kalochristianakis, Dimos D. Mitsikostas, Anastasios Orologas, Antonios Tavernarakis, Thomas Thomaidis, Krisztina Kovács, K Mátyás, Pálma Piros, Mária Sátori, K.J.S. Anand, Alexander L. Shifrin, Krzysztof Banaszkiewicz, Robert Bonek, M. Chahwan, M. Czernichowska - Kotiuszko, Lidia Darda-Ledzion, J. D. Wojcik, M Dziki, Ewa Krzystanek, Marianna Kulka, Paweł Lisewski, Marcin Ratajczak, Andrzej Szczudlik, Jarosław Szczygieł, Małgorzata Pańczyk-Tomaszewska, Jacek Wójcik, Daniel Zielonka, M. Chiru, Swaroopa Deme, S Mănescu, S.A. Nica, Christian Popescu, Szabolcs Szatmári, A. L. Fedyanin, N A Malkova, D.V. Popov, Л. И. Волкова, Vorob'eva Ov, M Brozman, Andrea Cimprichová, P. Cuchran, Ladislav Gurcik, Georgi Krastev, I. Lisá, M. Nyeky, J. Poljaková, Peter Turčáni, Adaani Frost, Josef G. Heckmann, Eduardo Agüera, Francisco Coret, Antonio Escartín, Victoria Fernández, JR. Ara Callizo, Greg S. Martin, José Rodríguez, M. Martinez Gines, Daniel Muñoz, Javier Olascoaga, José M. Prieto, Cristina Ramo‐Tello, Samir Belal, S. Ben Ammou, Mahbouba Frih-Ayed, Riadh Gouider, Chokri Mhiri, Ridha Mrissa, Alla Cherkez and 21 more - Neurology Neuroimmunology & Neuroinflammation 2022 cited by 67

  17. Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Patrick Vermersch, Orhun H. Kantarci, Aksel Sıva, Christina Azevedo, Naila Makhani, Mikaël Cohen, Daniel Pelletier, Darin T. Okuda, Sandra Vukusic, RISC, SFSEP, and OFSEP Investigators, Orhun H. Kantarci, Aksel Sıva, Daniel Pelletier, Darin T. Okuda, Christina Azevedo, Naila Makhani, Fataï Radji, Nathalie Morel, Deborah Grosset-Jeannin, Aurelian Ungureanu, L Boyer, Laurent Suchet, Zyad Elias, Christine Lebrun‐Frénay, Mikaël Cohen, Lydiane Mondot, Éric Thouvenot, Jonathan Ciron, Françoise Durand‐Dubief, Bruno Brochet, Aurélie Ruet, Jean‐Christophe Ouallet, Gilles Defer, Pierre Branger, Nathalie Derache, Pierre Clavelou, Frédéric Taithe, Adullatif Alkhedr, Agnès Fromont, Thibault Moreau, Ayman Tourbah, Olivier Casez, Éric Berger, Hélène Zéphir, Olivier Outteryck, Patrick Vermersch, Patrick Hautecoeur, G. Androdias, Iuliana Ionescu, Jean Pelletier, Bertrand Audoin, Adil Maarouf, Xavier Ayrignac, Clarisse Carra‐Dallière, Pierre Labauge, Marc Debouverie, Guillaume Mathey, Philippe Cabre, David Laplaud, Sandrine Wiertlevski, Saskia Bresch, Giovanni Castelnovo, Caroline Papeix, Céline Louapre, Élisabeth Maillart, Catherine Lubetzki, Bruno Stankoff, Bertrand Fontaine, C. Giannesini, Olivier Heinzleff and 70 more - JAMA Network Open 2021 cited by 86

  18. Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis

    Authors: , , , , , , , , , , , , , , , , - JAMA Network Open 2022 cited by 53

  19. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

    Authors: , , , , , , , , , - Multiple Sclerosis and Related Disorders 2019 cited by 142

  20. Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event

    Authors: , , , , , , , , , , , , , , , , , , , , , - PLoS ONE 2014 cited by 332

  21. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease

    Authors: , , , , , , , , , , , - Neurology 1999 cited by 809

  22. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Multiple Sclerosis and Related Disorders 2017 cited by 140

  23. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2025 cited by 111

  24. Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets

    Authors: , , , , , , , , , , , , , , , , , - Neurology Neuroimmunology & Neuroinflammation 2022 cited by 41